Tuesday, September 21, 2021 2:54:19 AM
pegs1, for that reason (a risk) I'm very happy to see RAM finally forging ahead with his own Aviptadil trials outside of the USA. It's going to make the FDA look very foolish for letting the ROW get ahead of it with Aviptadil.
It's like Dr Joey has stated...it's not a matter of "if", it's a matter of "when".
It's like Dr Joey has stated...it's not a matter of "if", it's a matter of "when".
Recent RLFTF News
- MindMaze Therapeutics Announces Initiation of Coverage by Baader Bank • ACCESS Newswire • 03/19/2026 06:35:00 AM
- MindMaze Therapeutics: Consolidating a Global Approach to Reimbursement for Next-Generation Therapeutics • ACCESS Newswire • 12/23/2025 06:20:00 AM
- Relief Therapeutics and NeuroX Complete Business Combination and Form MindMaze Therapeutics • ACCESS Newswire • 12/15/2025 06:20:00 AM
- Relief Therapeutics Shareholders Approve Business Combination with NeuroX • ACCESS Newswire • 11/14/2025 05:40:00 PM
- Relief Therapeutics Announces Positive Results from Pivotal Bioequivalence Study of RLF-OD032 • ACCESS Newswire • 10/29/2025 06:20:00 AM
- Micro-Cap Biotech Skyrockets on FDA Pediatric Disease Nod • AllPennyStocks.com • 05/22/2025 04:49:00 PM
